Have a feature idea you'd love to see implemented?
Let us know!
PDSB PDS Biotechnology Corp
Price (delayed)
$3.315
Market cap
$122.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$88.7M
PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively
Highlights
PDS Biotechnology's EPS has increased by 24% YoY and by 10% QoQ
PDS Biotechnology's net income has increased by 15% YoY and by 7% from the previous quarter
The quick ratio has plunged by 52% YoY and by 17% from the previous quarter
The equity has contracted by 17% from the previous quarter and by 4.7% YoY
Key stats
What are the main financial stats of PDSB
Market
Valuations
Earnings
Shares outstanding
36.82M
Market cap
$122.06M
Enterprise value
$88.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$39.71M
EBITDA
-$39.65M
Free cash flow
-$34.43M
Per share
Balance sheet
Liquidity
EPS
-$1.23
Free cash flow per share
-$0.94
Book value per share
$0.84
Revenue per share
$0
TBVPS
$1.65
Total assets
$60.5M
Total liabilities
$29.58M
Debt
$24.38M
Equity
$30.92M
Working capital
$44.49M
Debt to equity
0.79
Current ratio
3.84
Quick ratio
3.68
Net debt/EBITDA
0.84
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-66.1%
Return on equity
-137.1%
Return on invested capital
-297.9%
Return on capital employed
-88.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PDSB stock price
How has the PDS Biotechnology stock price performed over time
Intraday
2.95%
1 week
6.42%
1 month
-13.22%
1 year
-21.07%
YTD
-33.3%
QTD
-13.22%
Financial performance
How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.71M
Net income
-$40.68M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 18% YoY and by 9% from the previous quarter
PDS Biotechnology's net income has increased by 15% YoY and by 7% from the previous quarter
Growth
What is PDS Biotechnology's growth rate over time
Valuation
What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
3.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 24% YoY and by 10% QoQ
The P/B is 22% lower than the last 4 quarters average of 4.9 but 6% higher than the 5-year quarterly average of 3.6
The equity has contracted by 17% from the previous quarter and by 4.7% YoY
Efficiency
How efficient is PDS Biotechnology business performance
PDS Biotechnology's ROIC has decreased by 24% YoY and by 3.2% from the previous quarter
PDSB's ROE is down by 18% YoY but it is up by 6% QoQ
The ROA is up by 6% QoQ
Dividends
What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PDSB.
Financial health
How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 105% more than its total liabilities
PDSB's current ratio has dropped by 52% year-on-year and by 16% since the previous quarter
The quick ratio has plunged by 52% YoY and by 17% from the previous quarter
PDS Biotechnology's debt is 21% lower than its equity
The debt to equity is up by 22% since the previous quarter and by 10% year-on-year
The equity has contracted by 17% from the previous quarter and by 4.7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.